Tomohiro Nishino

Tomohiro Nishino

Auto-generated profile, based on publicly available information

Tomohiro Nishino

Gladstone Institutes, San Francisco, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2024 in Nature
Verified
Journal Article
Closed access
PDF file
MAMichael Alexanian
Michael Alexanian
APArun Padmanabhan
Arun Padmanabhan
TNTomohiro Nishino
Tomohiro Nishino
JTJoshua G. Travers
Joshua G. Travers
LYLin Ye
Lin Ye
DSDeepak Srivastava
Deepak Srivastava

10 December 2020 in Science
Verified
Journal Article
Closed access
PDF file
CTChristina V. Theodoris
Christina V. Theodoris
PZPing Zhou
Ping Zhou
LLLei Liu
Lei Liu
Yu ZhangYu Zhang
Yu Zhang
TNTomohiro Nishino
Tomohiro Nishino
DSDeepak Srivastava
Deepak Srivastava
Machine learning for medicine: Small-molecule screens aimed at identifying therapeutic candidates traditionally search for molecules that affect one to several outputs at most, limiting discovery of true disease-modifying drugs. Theodoris et al. developed a machine-learning approach to identify small molecules that broadly correct gene networks dysregulated in a human induced pluripotent stem cell disease model of a common form of heart disease involving the aortic valve. Gene network correction by the most efficacious therapeutic candidate generalized to primary aortic valve cells derived from more than 20 patients with sporadic aortic valve disease and prevented aortic valve disease in vivo in a mouse model. Science , this issue p. eabd0724

16 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
THTakahiro Horie
Takahiro Horie
TNTetsushi Nakao
Tetsushi Nakao
YMYui Miyasaka
Yui Miyasaka
TNTomohiro Nishino
Tomohiro Nishino
Shigenobu MatsumuraShigenobu Matsumura
Shigenobu Matsumura
KOKoh Ono
Koh Ono
Adaptive thermogenesis is essential for survival, and therefore is tightly regulated by a central neural circuit. Here, we show that microRNA (miR)-33 in the brain is indispensable for adaptive thermogenesis. Cold stress increases miR-33 levels in the hypothalamus and miR-33−/− mice are unable to maintain body temperature in cold environments due to reduced sympathetic nerve activity and impaired brown adipose tissue (BAT) thermogenesis. Analysis of miR-33f/f dopamine-β-hydroxylase (DBH)-Cre mice indicates the importance of miR-33 in Dbh-positive cells. Mechanistically, miR-33 deficiency upregulates gamma-aminobutyric acid (GABA)A receptor subunit genes such as Gabrb2 and Gabra4. Knock-down of these genes in Dbh-positive neurons rescues the impaired cold-induced thermogenesis in miR-33f/fDBH-Cre mice. Conversely, increased gene dosage of miR-33 in mice enhances thermogenesis. Thus, miR-33 in the brain contributes to maintenance of BAT thermogenesis and whole-body metabolism via enhanced sympathetic nerve tone through suppressing GABAergic inhibitory neurotransmission. This miR-33-mediated neural mechanism may serve as a physiological adaptive defense mechanism for several stresses including cold stress.

14 September 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
GSGeoffrey A. Smith
Geoffrey A. Smith
APArun Padmanabhan
Arun Padmanabhan
BLBryan H. Lau
Bryan H. Lau
APAkhil Pampana Pampana
Akhil Pampana Pampana
LLLi Li
Li Li
JCJohn S. Chorba
John S. Chorba
The low-density lipoprotein receptor (LDLR) controls cellular delivery of cholesterol and clears LDL from the bloodstream, protecting against atherosclerotic heart disease, the leading cause of death in the United States. We therefore sought to identify regulators of the LDLR beyond the targets of current therapies and known causes of familial hypercholesterolemia. We found that cold shock domain–containing protein E1 (CSDE1) enhanced hepatic LDLR messenger RNA (mRNA) decay via its 3′ untranslated region and regulated atherogenic lipoproteins in vivo. Using parallel phenotypic genome-wide CRISPR interference screens in a tissue culture model, we identified 40 specific regulators of the LDLR that were not previously identified by observational human genetic studies. Among these, we demonstrated that, in HepG2 cells, CSDE1 regulated the LDLR at least as strongly as statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. In addition, we showed that hepatic gene silencing of Csde1 treated diet-induced dyslipidemia in mice to a similar degree as Pcsk9 silencing. These results suggest the therapeutic potential of targeting CSDE1 to manipulate the posttranscriptional regulation of the LDLR mRNA for the prevention of cardiovascular disease. Our approach of modeling a clinically relevant phenotype in a forward genetic screen, followed by mechanistic pharmacologic dissection and in vivo validation, may serve as a generalizable template for the identification of therapeutic targets in other human disease states.

23 February 2024 in Nature Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
APArun Padmanabhan
Arun Padmanabhan
TST. Yvanka de Soysa
T. Yvanka de Soysa
APAngelo Pelonero
Angelo Pelonero
VSValerie Sapp
Valerie Sapp
PSParisha P. Shah
Parisha P. Shah
RJRajan Jain
Rajan Jain

22 October 2025 in Nature
Verified
Journal Article
Open access
PDF file
SRSanjeev S. Ranade
Sanjeev S. Ranade
FLFeiya Li
Feiya Li
SWSean Whalen
Sean Whalen
APAngelo Pelonero
Angelo Pelonero
LYLin Ye
Lin Ye
DSDeepak Srivastava
Deepak Srivastava
Congenital heart defects (CHDs) are the most common developmental abnormalities, affecting around 1% of live births1. Aneuploidy causes around 15% of CHDs, with trisomy 21 (also known as Down syndrome) being the most frequent form2. CHDs occur in around 50% of cases of Down syndrome, with an approximately 1,000-fold enrichment of atrioventricular canal (AVC) defects that disrupt the junction between the atria and ventricles3,4. The AVC contains unique myocardial cells that are essential for valvuloseptal development; however, the specific combination of dosage-sensitive genes on chromosome 21 that are responsible for Down syndrome-associated CHDs have remained unknown. Here, using human pluripotent stem cell and mouse models of Down syndrome, we identify HMGN1, a nucleosome-binding epigenetic regulator encoded on chromosome 21, as a key contributor to these defects. Single-cell transcriptomics showed that trisomy 21 shifts human AVC cardiomyocytes towards a ventricular cardiomyocyte state. A CRISPR-activation single-cell RNA droplet sequencing (CROP-seq) screen of chromosome 21 genes expressed during heart development revealed that HMGN1 upregulation mimics this shift, whereas deletion of one HMGN1 allele in trisomic cells restored normal gene expression. In a mouse model of trisomy 21, a similar transcriptional shift of AVC cardiomyocytes was restored by a reduction in Hmgn1 dosage, leading to rescue of valvuloseptal defects. These findings identify HMGN1 as a dosage-sensitive modulator of AVC development and cardiac septation in Down syndrome. This study offers a paradigm for dissecting aneuploidy-associated pathogenesis using isogenic systems to map causal genes in complex genetic syndromes.